Celgene and Acceleron announce submission of luspatercept MAA to the EMA for MDS
Celgene and Acceleron announced that Celgene has submitted a Marketing Authorization Application to the EMA for luspatercept for treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts. April 26, 2019